methylene blue had some formulation issues and thay have re-engineered a new product. It is in phase 1, but have heeard that they are trying to get a partner and go straight to ph 3.
Bapinuzumab showed a 25% reduction in total tau and phosphotau in ph 2 that was very near statisitical significancee with a small sample size. i think this is promising and one of the reasons I came to believe more in this program.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.